Quinn, T., Gaughan, E., Bruce, A., Antonelli, J., O'Connor, R., Li, F., McNamara, S., Koch, O., Mackintosh, C., Dockrell, D., Walsh, T., Blyth, K., Church, C., Schwarze, J., Boz, C., Valanciute, A., Burgess, M., Emanuel, P., Mills, B., Rinaldi, G., Hardisty, G., Mills, R., Gwyer Findlay, E., Jabbal, S., Duncan, A., Plant, S., Marshall, A., Young, I., Russell, K., Scholefield, E., Nimmo, A., Moore, A., Finlayson, K., Shankar-Hari, M., Parker, R., Akram, A., Dear, J., Hirani, N. & Dhaliwal, K. 2022, 'Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics', EBioMedicine, 76, article no: 103856. https://doi.org/10.1016/j.ebiom.2022.103856